LAM development is driven by Trem2 and characterized by upregulation of components of an enzymatic machinery that recognizes, scavenges, and catabolizes lipids such as fatty acids transporter Cd36, fatty acid binding proteins 5 (Fabp5) and lipoprotein lipase (Lpl). Here, LPL is linked to lymphangioleiomyomatosis.